



Marine Sponge Biotechnology

Guest Editors:

Prof. Dr. Micha Ilan

Prof. Dr. Shmuel Carmeli

Dr. Michelle Kelly

Prof. Dr. Mark T. Hamann

Deadline for manuscript
submissions:

closed (5 March 2022)

Message from the Guest Editors

Sponges, the oldest animals on Earth, have been found to be a trove for biotechnological prospecting. From the early discoveries of novel marine drugs with pharmaceutical applications, sponges' immense arsenal of secondary metabolites have been proven to have many potential applications, including as cosmeceuticals, industrial enzymes, agrochemicals, and nutraceuticals. Sponge-derived skeletons and compounds have been used for regenerative medicine and suggested as drug carriers. Biomimetic and bioinspired processes have been shown to have many beneficial uses. The utilization of sponges for bioremediation, or as bioindicators, has been demonstrated. Methods of acquiring novel sponge-derived compounds and obtaining large amounts of sought-after molecules demand the employment of many techniques. These include aquaculture, microbial culture, cell culture, gene mining, natural product chemistry, and other biotechnological approaches, taking advantage of the rapid improvements in various omics methods and new instrumentation.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Bill J. Baker

Department of Chemistry,
University of South Florida, 4202
E. Fowler Ave., CHE 205, Tampa,
FL 33620-5250, USA

Message from the Editor-in-Chief

During the past few decades there has been an ever increasing number of novel compounds discovered in the marine environment. This is exemplified by the robust preclinical and clinical pipeline that currently exists for marine natural products. *Marine Drugs* is inviting contributions on new advances in marine biotechnology, pharmacology, chemical ecology, synthetic biology, and genomics approaches related to the discovery of therapeutically relevant marine natural products. Our goal is to share your contribution in a timely fashion and in a manner that will be valued by the scientific community.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [MEDLINE](#), [PMC](#), [Embase](#), [PubAg](#), [MarinLit](#), [AGRIS](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmacology, Toxicology and Pharmaceutics (miscellaneous)*)

Contact Us

Marine Drugs Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/marinedrugs
marinedrugs@mdpi.com
X@Marine_Drugs